Cat. No.: 188-0P
Amount: 100 µg
Price:
$110.00
|
|
|
| Cat. No. 188-0P |
100 µg protein, lyophilized. For reconstitution add 100 µl H2O to get a 1mg/ml solution in TBS. Then aliquot and store at -20°C to -80°C until use. Control proteins should be stored at +4°C when still lyophilized. Do not freeze! |
| Applications |
|
| Immunogen | Recombinant protein corresponding to residues near the amino terminus of human Map2 (UniProt Id: P11137-4) |
| Recommended dilution | Optimal concentrations should be determined by the end-user. |
| Matching antibodies | 188 002, 188 003, 188 004, 188 006, 188 011, 188 011BT, 188 111 |
| Remarks |
This control protein consists of the recombinant protein (aa 2-314 of human MAP 2 isoform 4) that has been used for immunization. It has been tested in preadsorption experiments and blocks efficiently and specifically the corresponding signal in Western blots. The amount of protein needed for efficient blocking depends on the titer and on the affinity of the antibody to the antigen. |
| Data sheet | 188-0p.pdf |
|
|
There are two major classes of heat-stable microtubule-associated proteins (MAPs): MAP2 and tau (MAPT). Both bind microtubules and regulate their polymerization and stability—a critical process for maintaining cellular architecture and dynamics (1).
MAP2 exists in four main isoforms—MAP2A, MAP2B, MAP2C, and MAP2D—via alternative splicing. The high molecular weight isoforms MAP2A/B (~250 kDa) and lower molecular weight isoforms MAP2C/D (~70 kDa) all share a conserved microtubule-binding core domain, important for dendritic stabilization and neuritogenesis (2).
Since microtubule dynamics are central to cell division, migration, and morphology, aberrations in MAP2 and tau expression have been implicated in several types of cancer.
Consequently, MAP2 expression has diagnostic and prognostic relevance in neuro-oncology. MAP2 immunoreactivity helps distinguish glial neoplasms in neuropathology, and its expression tends to vary according to tumor grade (3). While classic low-grade gliomas often show robust MAP2 staining, higher-grade tumors may exhibit less-specific and more heterogeneous patterns. Moreover, in melanoma, reduced MAP2 expression correlates with increased tumor aggressiveness, underscoring its potential role as a tumor suppressive marker (4).